Sjögren Syndrome and Cancer

Igoe, Ann; Merjanah, Sali; Scofield, R. Hal

doi:10.1016/j.rdc.2020.05.004

Cited by 14 publications

(9 citation statements)

References 107 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, in SS, APOE polymorphisms were significantly associated with the early onset of disease ( Pertovaara, 2004 ). Additionally, although the patients we evaluated here did not have cancer, SS patients are more susceptible to cancer development ( Brito-Zerón et al, 2016 ; Igoe et al, 2020 ); yet, the specific reason is not known but sustained and increased inflammation observed in SS patients could be associated with increased cancer risk. The expression of cystatin S (CTS3) was reported to be significantly elevated in saliva from SS patients ( van der Reijden et al, 1996 ) and here we found a potential association of cystatin S with collagen catabolic process, neutrophils and immune system enrichment pathways.…”

Section: Discussionmentioning

confidence: 96%

Proteomics Analysis of Tears and Saliva From Sjogren’s Syndrome Patients

et al. 2021

View full text Add to dashboard Cite

Sjogren’s syndrome (SS) is characterized by dysfunctional mucous membranes and dysregulated moisture-secreting glands resulting in various symptoms, including dry mouth and dry eyes. Here, we wanted to profile and compare the tear and saliva proteomes of SS patients to healthy controls. Tear and saliva samples were collected and subjected to an isotopic dimethylation labeling shotgun proteomics workflow to identify alterations in protein levels. In tear samples, we identified 83 upregulated and 112 downregulated proteins. Pathway enrichment analysis of the changing proteins by Metascape identified leukocyte transendothelial migration, neutrophil degranulation, and post-translation protein phosphorylation in tears of SS patients. In healthy controls’ tears, an enrichment for proteins related to glycolysis, amino acid metabolism and apoptotic signaling pathway were identified. In saliva, we identified 108 upregulated and 45 downregulated proteins. Altered pathways in SS patients’ saliva included cornification, sensory perception to taste and neutrophil degranulation. In healthy controls’ saliva, an enrichment for proteins related to JAK-STAT signaling after interleukin-12 stimulation, phagocytosis and glycolysis in senescence were identified. Dysregulated protease activity is implicated in the initiation of inflammation and immune cell recruitment in SS. We identified 20 proteases and protease inhibitors in tears and 18 in saliva which are differentially expressed between SS patients and healthy controls. Next, we quantified endogenous proteoglycan 4 (PRG4), a mucin-like glycoprotein, in tear wash and saliva samples via a bead-based immune assay. We identified decreased levels of PRG4 in SS patients’ tear wash compared to normal samples. Conversely, in saliva, we found elevated levels of PRG4 concentration and visualized PRG4 expression in human parotid gland via immunohistological staining. These findings will improve our mechanistic understanding of the disease and changes in SS patients’ protein expression will help identify new potential drug targets. PRG4 is among the promising targets, which we identified here, in saliva, for the first time.

show abstract

Section: Discussionmentioning

confidence: 96%

Proteomics Analysis of Tears and Saliva From Sjogren’s Syndrome Patients

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The most common cancer is lymphoma. Patients with primary Sjogren's syndrome (pSS) are 10-44 times more likely to develop lymphoma than healthy individuals (Igoe et al, 2020). In order to lay the foundation of risk stratification and targeted cancer screening, larger longitudinal cohort studies that provide a more detailed framework of the links between cancer and autoimmunity are urgently needed.…”

Section: Relationship Between Autoimmune Diseases and Cancermentioning

confidence: 99%

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

Zhang

Kong

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Autoimmune diseases and malignant tumors are the two hotspots and difficulties that are currently being studied and concerned by the medical field. The use of PD-1/PD-L1 inhibitors improves the prognosis of advanced tumors, but excessive immune responses can also induce immune-related adverse events (irAEs). Due to this concern, many clinical trials exclude cancer patients with preexisting autoimmune disease (AID). This review outlines the possible mechanisms of irAE, discusses the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients with preexisting AID, and emphasizes the importance of early recognition, continuous monitoring, and multidisciplinary cooperation in the prevention and management of cancer patients with preexisting AID.

show abstract

“…It occurs in 5-7% of primary and secondary SS patients, who carry a 7-fold increased risk of developing lymphoma than the normal population (83). In most cases, lymphomas arise from salivary glands, particularly the parotid glands, but they can also involve nodes or extranodal organs, including the lung (83)(84)(85). The chronic polyclonal lymphocytic infiltration of airways and lung parenchyma can progress to a monoclonal B-cell proliferation, with a high risk for NHL development (12).…”

Section: Lymphoma and Other Malignanciesmentioning

confidence: 99%

“…Since an association between lung adenocarcinoma and LIP in patients with pSS has been reported, the appearance of new nodular lesions at chest CT should include lung cancer in the differential diagnosis (Fig. 9) (84,95).…”

Section: Lymphoma and Other Malignanciesmentioning

confidence: 99%

Chest high-resolution computed tomography in primary Sjögren's syndrome: an up-to-date primer for rheumatologists

Cereser

Giovannini

Caronia

et al. 2022

Clinical and Experimental Rheumatology

View full text Add to dashboard Cite

Pulmonary manifestations, including airway involvement and interstitial lung disease, are the most frequent extra-glandular complications of primary Sjögren's syndrome (pSS). Chest high-resolution computed tomography (HRCT) is a cornerstone of pulmonary diagnostic imaging, aiming to detect, characterise, and quantify such conditions. In patients with pSS-related lung abnormalities, HRCT proved helpful in various clinical scenarios, including baseline and follow-up evaluation, assessment of superimposed infections, suspected progressive interstitial lung diseases, and acute exacerbation. This review aims to provide a primer for rheumatologists on chest HRCT, illustrating the up-to-date technique, imaging findings, and clinical indications in pSS and highlighting the importance of rheumatologist-radiologist constructive collaboration in the clinical management of such patients. Chest HRCT examination State-of-art techniqueRadiologists should perform chest HRCT according to updated recommendations to make the most of its potential, as highlighted in Table I (8,(19)(20)(21)(22)(23). Anatomo-radiologic correlationChest HRCT interpretation should rely on a basic understanding of pulmonary anatomy (19). In this regard, the sec-

show abstract

Sjögren Syndrome and Cancer

Cited by 14 publications

References 107 publications

Proteomics Analysis of Tears and Saliva From Sjogren’s Syndrome Patients

Proteomics Analysis of Tears and Saliva From Sjogren’s Syndrome Patients

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases

Chest high-resolution computed tomography in primary Sjögren's syndrome: an up-to-date primer for rheumatologists

Contact Info

Product

Resources

About